Revolution Medicines' KRAS inhibitor daraxonrasib draws attention beyond pancreatic cancer after ASCO data

STAT News reported on 4 June 2026 that discussion within oncology has moved rapidly from the initial positive trial data for Revolution Medicines' daraxonrasib — a RAS(ON) inhibitor targeting KRAS(G12D) — towards its potential application in tumour types beyond pancreatic ductal adenocarcinoma (PDAC).

Daraxonrasib targets the active, GTP-bound form of KRAS(G12D), the most common KRAS mutation in PDAC and a long-sought but historically undruggable target. The drug has not yet received regulatory approval; the ASCO 2026 data that drew widespread attention described response rates and survival signals in PDAC patients, a disease historically associated with very poor prognosis and limited systemic therapy options.

The STAT News piece, which sits behind a STAT+ paywall, reports that researchers and industry observers are now discussing expansion into colorectal cancer and non-small cell lung cancer, where KRAS(G12D) mutations also occur, albeit at lower frequencies than in PDAC. The article notes that any such expansion would require dedicated clinical trials.

Genetic Current covered the primary ASCO trial results for daraxonrasib in PDAC on 1 June 2026. The present item represents follow-on commentary rather than new primary data. It is included here because the discussion of KRAS mutation prevalence across tumour types is of substantive educational relevance to oncologists and researchers working in cancer genomics.